Sadiye Amcaoglu Rieder

TL;DR: This review will focus on the potential use of cannabinoids as a new class of anti-inflammatory agents against a number of inflammatory and autoimmune diseases that are primarily triggered by activated T cells or other cellular immune components.

TL;DR: This review will focus on apoptotic mechanisms of immunosuppression mediated by cannabinoids on different immune cell populations and discuss how activation of CB2 provides a novel therapeutic modality against inflammatory and autoimmune diseases as well as malignancies of the immune system, without exerting the untoward psychotropic effects.

TL;DR: It is shown that the selective deletion of Helios in Tregs leads to slow, progressive systemic immune activation, hypergammaglobulinemia, and enhanced germinal center formation in the absence of organ-specific autoimmunity.

TL;DR: Efficient production and properties of engineered antigen-specific Tregs are reported, created by transduction of a recombinant T-cell receptor obtained from a hemophilia A subject's T- cell clone, into expanded human FoxP3(+) T Regs, suggesting potential utility to treat anti-FVIII inhibitory antibody formation in hemophili A patients.

TL;DR: It is shown that the TIGIT/FCRL3 combination allows reliable identification of Helios+ Treg cells even in highly activated conditions in vitro as well as in PBMCs of autoimmune patients.